Search

Your search keyword '"Chretien, M. L."' showing total 22 results
Start Over Author "Chretien, M. L."
22 results on '"Chretien, M. L."'

6. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

Author

Schavgoulidze, A., primary, Perrot, A., additional, Cazaubiel, T., additional, Leleu, X., additional, Manier, S., additional, Buisson, L., additional, Maheo, S., additional, Do Souto Ferreira, L., additional, Lannes, R., additional, Pavageau, L., additional, Hulin, C., additional, Marolleau, J.-P., additional, Voillat, L., additional, Belhadj, K., additional, Divoux, M., additional, Slama, B., additional, Brechignac, S., additional, Macro, M., additional, Stoppa, A.-M., additional, Sanhes, L., additional, Orsini-Piocelle, F., additional, Fontan, J., additional, Chretien, M.-L., additional, Demarquette, H., additional, Mohty, M., additional, Avet-Loiseau, H., additional, and Corre, J., additional

Published
2022
Full Text
View/download PDF

7. S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04

Author

Touzeau, C., primary, Perrrot, A., additional, Hulin, C., additional, Manier, S., additional, Macro, M., additional, Chretien, M.-L., additional, Karlin, L., additional, Decaux, O., additional, Jacquet, C., additional, Tiab, M., additional, Leleu, X., additional, Planchce, L., additional, Avet-Loiseau, H., additional, and Moreau, P., additional

Published
2022
Full Text
View/download PDF

12. CARFILZOMIB WEEKLY PLUS MELPHALAN AND PREDNISONE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA (IFM 2012-03) / 21st Congress of the European-Hematology-Association

Author

Leleu, X., Fouquet, G., Karlin, L., Kolb, B., Tiab, M., Araujo, C., Meuleman, N., Revel, T., Bourquard, P., Lenain, P., Roussel, Mikael, Jaccard, A., Petillon, M. O., Belhadj-Merzoug, K., Lepeu, G., Chretien, M. L., Fontan, J., Rodon, P., Schmitt, Anne, Offner, F., Voillat, L., Cerejat, S., Kuhnowsko, F., Rigaudeau, S., Decaux, O., Humbrecht-Kraut, C., Frayfer, J., Fitoussi, O., Weil, D. Roos, Eisenmann, J. C., Dorvaux, V., Voog, E. G., Hulin, C., Attal, M., Moreau, P., Facon, T., Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Jonchère, Laurent

Subjects
[SDV.GEN]Life Sciences [q-bio]/Genetics, [SDV.GEN] Life Sciences [q-bio]/Genetics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

13. Expressed fusion gene landscape and its impact in multiple myeloma

Author

Cleynen, A., primary, Szalat, R., additional, Kemal Samur, M., additional, Robiou du Pont, S., additional, Buisson, L., additional, Boyle, E., additional, Chretien, M. L., additional, Anderson, K., additional, Minvielle, S., additional, Moreau, P., additional, Attal, M., additional, Parmigiani, G., additional, Corre, J., additional, Munshi, N., additional, and Avet-Loiseau, H., additional

Published
2017
Full Text
View/download PDF

14. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

Author

Duchmann, M, primary, Braun, T, additional, Micol, J-B, additional, Platzbecker, U, additional, Park, S, additional, Pilorge, S, additional, Beyne-Rauzy, O, additional, Vey, N, additional, Sébert, M, additional, Gruson, B, additional, Dumas, P-Y, additional, Guieze, R, additional, Chretien, M-L, additional, Laribi, K, additional, Chait, Y, additional, Legros, L, additional, Sahnes, L, additional, Hirsch, P, additional, Salanoubat, C, additional, Solary, E, additional, Fenaux, P, additional, and Itzykson, R, additional

Published
2017
Full Text
View/download PDF

18. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

Author

Chretien, M.-L., primary, Hebraud, B., additional, Cances-Lauwers, V., additional, Hulin, C., additional, Marit, G., additional, Leleu, X., additional, Karlin, L., additional, Roussel, M., additional, Stoppa, A.-M., additional, Guilhot, F., additional, Lamy, T., additional, Garderet, L., additional, Pegourie, B., additional, Dib, M., additional, Sebban, C., additional, Lenain, P., additional, Brechignac, S., additional, Royer, B., additional, Wetterwald, M., additional, Legros, L., additional, Orsini-Piocelle, F., additional, Voillat, L., additional, Delbrel, X., additional, Caillot, D., additional, Macro, M., additional, Facon, T., additional, Attal, M., additional, Moreau, P., additional, Avet-Loiseau, H., additional, and Corre, J., additional

Published
2014
Full Text
View/download PDF

20. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association

Author

Debarri, H., Lebon, D., Roumier, C., Meyling Cheok, Marceau-Renaut, A., Nibourel, O., Geffroy, S., Helevaut, N., Rousselot, P., Gruson, B., Gardin, C., Chretien, M. L., Sebda, S., Figeac, M., Berthon, C., Quesnel, B., Boissel, N., Castaigne, S., Dombret, H., Renneville, A., and Preudhomme, C.

Subjects
Adult, Neoplasm, Residual, acute myeloid leukemia, Sensitivity and Specificity, DNA Methyltransferase 3A, Young Adult, hemic and lymphatic diseases, Biomarkers, Tumor, Humans, DNA (Cytosine-5-)-Methyltransferases, Aged, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, High-Throughput Nucleotide Sequencing, Nuclear Proteins, Middle Aged, Prognosis, Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute Disease, Mutation, minimal residual disease, next-generation sequencing, France, Neoplasm Recurrence, Local, Clinical Research Paper, Nucleophosmin
Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in next-generation sequencing (NGS) have provided the opportunity to use multiple molecular markers. In this study, we used NGS technology to assess MRD in 31 AML patients enrolled in the ALFA-0701 trial and harboring NPM1 mutations associated to IDH1/2 or DNMT3A mutations. NPM1 mutation-based MRD monitoring was performed by RTqPCR. IDH1/2 and DNMT3A mutations were quantified by NGS using an Ion Torrent Proton instrument with high coverage (2 million reads per sample). The monitoringof IDH1/2 mutations showed that these mutations were reliable MRD markers that allowed the prediction of relapse in the majority of patients. Moreover, IDH1/2 mutation status predicted relapse or disease evolution in 100% of cases if we included the patient who developed myelodysplastic syndrome. In contrast, DNMT3A mutations were not correlated to the disease status, as we found that a preleukemic clone with DNMT3A mutation persisted in 40% of the patients who were in complete remission, reflecting the persistence of clonal hematopoiesis.

21. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole].

Author

McLaughlin BE, Chretien ML, Choi C, Brien JF, Nakatsu K, and Marks GS

Subjects
Animals, Aorta, Thoracic enzymology, Drug Synergism, Guanylate Cyclase metabolism, In Vitro Techniques, Male, Muscle Relaxation drug effects, Muscle, Smooth, Vascular enzymology, Rats, Rats, Sprague-Dawley, Aorta, Thoracic drug effects, Carbon Monoxide pharmacology, Indazoles pharmacology, Muscle, Smooth, Vascular drug effects, Platelet Aggregation Inhibitors pharmacology
Abstract

The hypothesis that endogenous carbon monoxide (CO), produced during the oxidation of heme catalyzed by heme oxygenase (HO), plays a role similar to that of nitric oxide (NO) in the regulation of cardiovascular tone has been criticized because of the low potency of CO compared with NO in relaxing blood vessels and stimulating soluble guanylyl cyclase (sGC). This criticism has been muted by the demonstration that, in the presence of YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole], CO has similar potency to NO in stimulating sGC activity. In this study, we determined that YC-1 potentiated CO-induced relaxation of rat aortic strips (RtAS) by approximately ten-fold. Furthermore, CO-induced relaxation of RtAS was shown to be mediated through stimulation of sGC because vasorelaxation was inhibited by ODQ (1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one), a selective sGC inhibitor, in the absence and presence of YC-1. A gas chromatographic-headspace method was used to measure CO concentration in Krebs' solution following the addition of CO-saturated saline solution to the tissue bath, in order to provide an accurate determination of RtAS exposure to CO. The tissue bath concentration of CO was shown to be approximately one-half of that calculated to be present. We conclude that should an endogenous compound exist with properties similar to that of YC-1, then the potency of CO as a vasorelaxant in the presence of this factor would be increased. As a consequence, CO could play a role in the regulation of cardiovascular tone, comparable to that of NO.

Published
2000

22. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations.

Author

Appleton SD, Chretien ML, McLaughlin BE, Vreman HJ, Stevenson DK, Brien JF, Nakatsu K, Maurice DH, and Marks GS

Subjects
Animals, Brain enzymology, Dose-Response Relationship, Drug, Lung enzymology, Male, Rats, Rats, Sprague-Dawley, Enzyme Inhibitors pharmacology, Guanylate Cyclase antagonists & inhibitors, Heme Oxygenase (Decyclizing) antagonists & inhibitors, Metalloporphyrins pharmacology, Nitric Oxide Synthase antagonists & inhibitors
Abstract

Studies on the physiological role of heme oxygenase (HO) require an inhibitor that will selectively inhibit HO activity without inhibiting the activity of either nitric oxide synthase (NOS) or soluble guanylyl cyclase (sGC). The objective of this study was to test a series of metalloporphyrins that have previously been shown to inhibit HO activity, for their ability to inhibit HO without inhibiting NOS or sGC activities. Measurement of activity of HO in rat brain microsomes and NOS in rat brain cytosol was made for samples incubated with metalloporphyrins (0.15-50 microM), including zinc protoporphyrin IX, zinc deuteroporphyrin IX 2,4-bis-ethylene glycol (ZnBG), chromium mesoporphyrin IX (CrMP), tin protoporphyrin IX, and zinc N-methylprotoporphyrin IX. CrMP and ZnBG were found to be the most selective inhibitors of HO activity (i.e., caused the greatest inhibition of HO activity, 89 and 80%, respectively, without inhibition of NOS activity). Based on these results, sGC activity in rat lung cytosol incubated with CrMP or ZnBG (0.15-15 microM) was measured. ZnBG did not affect basal sGC activity but did potentiate S-nitroso-N-acetylpenicillamine (SNAP)-induced sGC activity. CrMP did not affect either basal or SNAP-induced activity. It was concluded that of the five metalloporphyrins studied, CrMP, at a concentration of 5 microM, was a selective inhibitor of HO activity and was the most useful metalloporphyrin for the conditions tested. Thus, CrMP would appear to be a valuable chemical probe in elucidating the physiological role of HO.

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results